sonesitatug vedotin + rilvegostomig + 5-fluorouracil + capecitabine

This is an investigational combination therapy comprising four drugs: - **sonesitatug vedotin** (AZD0901/CMG901): a Claudin 18.2-targeted antibody-drug conjugate (ADC) delivering monomethyl auristatin E, a microtubule inhibitor, for selective killing of tumor cells expressing CLDN18.2. - **rilvegostomig** (AZD2936): a PD-1/CTLA-4 bispecific monoclonal antibody, functioning as an immune checkpoint inhibitor, currently in early phase clinical trials. - **5-fluorouracil**: a pyrimidine analog antimetabolite that inhibits thymidylate synthase, impairing DNA synthesis. - **capecitabine**: an oral prodrug of 5-fluorouracil, also inhibiting thymidylate synthase after conversion in vivo. The combination is under clinical study for treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing Claudin 18.2[2][3].